Protein Sciences in Drug Discovery 2022
Poster
7

The drug-induced interface that drives HIV-1 integrase hypermultimerization and loss of function

Abstract

Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an emerging class of small molecules that disrupt viral maturation by inducing aberrant multimerization of IN. Here, we present co-crystal structures of HIV‑1 IN with two potent ALLINIs, BI-D and the drug candidate STP0404. The structures reveal atomistic details of the ALLINI-induced interface of the IN catalytic core and carboxyl-terminal domains (CCD and CTD). Projecting from their principal binding pocket on the HIV-1 IN CCD dimer, the compounds harness a triad of invariant IN CTD residues, Tyr226, Trp235, and Lys266, to nucleate the CTD-CCD interaction. The ALLINI-induced interface primarily involves the CTD SH3-like fold and extends to the beginning of the IN carboxyl-terminal tail. We show that mutations of HIV‑1 IN CTD residues that participate in the interface with the CCD greatly reduce the IN-aggregation properties of STP0404. Our results provide a reliable template for the rational development of this series of antiretrovirals through optimization of their key contacts with the viral target.

supporting document

Hosted By

ELRIG

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis

Get the App

Get this event information on your mobile by
going to the Apple or Google Store and search for 'myEventflo'
iPhone App
Android App
www.myeventflo.com/2424